Literature DB >> 26408733

Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.

Elisabeth A Kastelijn1, Sherif Y El Sharouni2, Frederik N Hofman3, Bart P Van Putte3, Evelyn M Monninkhof4, Marco Van Vulpen2, Franz M N H Schramel5.   

Abstract

BACKGROUND: Surgical resection is the treatment of first choice for patients with stage I-II non-small cell lung cancer (NSCLC). However, stereotactic body radiotherapy (SBRT) has been shown to be a good alternative treatment. PATIENTS AND METHODS: Overall survival (OS), progression-free survival (PFS) and recurrence rates were compared between patients with stage I-II NSCLC treated with SBRT (n=53) and those treated with surgical resection (n=175). The propensity score method was used to correct for confounding by indication.
RESULTS: Before correction, the OS and PFS rates at 1 and 3 years were significantly different between SBRT and surgery, in favor of surgery. After correction, the OS and PFS after SBRT were not significantly different compared to surgery. The recurrence rates for the two treatments were also similar both before and after correction.
CONCLUSION: This retrospective study showed that clinical outcomes after SBRT are equal to those after surgery in patients with stage I-II NSCLC. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; clinical outcome; stage I-II; stereotactic body radiotherapy; surgery

Mesh:

Year:  2015        PMID: 26408733

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  A SUVmax-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making.

Authors:  L Ye; F Xu; S Shi; Z Zeng; X Jin; Y Huang; C Lu; J Gu; D Ge; J He
Journal:  Clin Transl Oncol       Date:  2018-01-11       Impact factor: 3.405

Review 2.  Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.

Authors:  Alexander Chi; Haiquan Chen; Sijin Wen; Haijuan Yan; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2017-05-22       Impact factor: 6.280

Review 3.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 4: systematic review of evidence involving SBRT and ablation.

Authors:  Henry S Park; Frank C Detterbeck; David C Madoff; Brett C Bade; Ulas Kumbasar; Vincent J Mase; Andrew X Li; Justin D Blasberg; Gavitt A Woodard; Whitney S Brandt; Roy H Decker
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

4.  A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer.

Authors:  Christopher Cao; Daniel Wang; Caroline Chung; David Tian; Andreas Rimner; James Huang; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2018-09-15       Impact factor: 5.209

5.  Selection of Patients in Ongoing Clinical Trials on Lung Cancer.

Authors:  Karlijn J G Schulkes; Cindy Nguyen; Frederiek van den Bos; Leontine J R van Elden; Marije E Hamaker
Journal:  Lung       Date:  2016-09-20       Impact factor: 2.584

6.  Patient-Centered Outcome Measures in Lung Cancer Trials.

Authors:  Karlijn J G Schulkes; Cindy Nguyen; Frederiek van den Bos; Marije E Hamaker; Leontine J R van Elden
Journal:  Lung       Date:  2016-06-10       Impact factor: 2.584

7.  Stereotactic body radiotherapy versus surgery for early-stage non-small cell lung cancer: an updated meta-analysis involving 29,511 patients included in comparative studies.

Authors:  Gustavo Arruda Viani; André Guimarães Gouveia; Michael Yan; Fernando Konjo Matsuura; Fabio Ynoe Moraes
Journal:  J Bras Pneumol       Date:  2022-04-29       Impact factor: 2.800

8.  Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Ming Li; Xiaodong Yang; Yuhan Chen; Xinyu Yang; Xiyu Dai; Fenghao Sun; Li Zhang; Cheng Zhan; Mingxiang Feng; Qun Wang
Journal:  Onco Targets Ther       Date:  2017-06-07       Impact factor: 4.147

Review 9.  Sublobar resection is associated with improved outcomes over radiotherapy in the management of high-risk elderly patients with Stage I non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Huan-Huan Wang; Chun-Ze Zhang; Bai-Lin Zhang; Jie Chen; Xian-Liang Zeng; Lei Deng; Mao-Bin Meng
Journal:  Oncotarget       Date:  2017-01-24

10.  Assessing the Need for Adjuvant Chemotherapy After Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Carcinoma.

Authors:  Raphaël Jumeau; Houda Bahig; Édith Filion; Marie-Pierre Campeau; Louise Lambert; David Roberge; Andrei-Bogdan Gorgos; Toni Vu
Journal:  Cureus       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.